Revenue
2017
2018
2020
2021
2022
2023
2024
2025
GYRE THERAPEUTICS, INC. (GYRE)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2018
2019
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $116.6M | $105.8M | $113.5M | $102.3M | $7.3M | $20.9M | — | $6,000 | $1.0M | — | — | $275,000 | $3.6M | $57.9M | $97.6M | $85.7M | $25.1M |
| Gross profit | — | $101.9M | $108.8M | $97.5M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Research & development | $13.7M | $12.0M | $13.8M | $16.7M | $68.9M | $53.0M | $43.9M | $21.5M | $12.8M | $11.6M | $6.0M | $5.3M | $6.6M | $49.1M | $95.2M | $64.5M | $40.2M |
| Operating expenses | $105.1M | $89.6M | $176.0M | $88.3M | $95.2M | $78.3M | $57.3M | $33.8M | $22.8M | $20.8M | $15.6M | $9.3M | $10.6M | $66.0M | $107.4M | $72.6M | $65.4M |
| Operating income | $11.5M | $16.2M | −$67.2M | $9.2M | −$87.9M | −$57.4M | −$57.3M | −$33.8M | −$21.8M | −$20.4M | −$13.8M | −$7.5M | −$10.1M | −$8.1M | −$9.7M | $13.1M | −$40.3M |
| EBITDAderived | $14.0M | $17.7M | −$66.2M | $10.3M | −$87.6M | −$57.2M | −$57.1M | −$33.7M | −$21.6M | −$20.0M | −$13.3M | −$6.8M | −$9.1M | −$5.9M | −$7.3M | $15.1M | −$38.5M |
| Net income | $9.9M | $17.9M | −$85.5M | $4.3M | −$87.9M | −$56.2M | −$55.2M | −$30.1M | −$21.6M | −$16.9M | −$14.8M | −$6.6M | −$10.0M | −$7.0M | −$8.5M | $10.9M | −$39.4M |
| Basic EPSper diluted share | $0.06 | $0.14 | -$1.41 | $0.04 | -$2.87 | -$2.93 | -$4.60 | -$2.68 | -$7.45 | -$21.75 | -$49.99 | -$17.99 | -$27.29 | -$0.21 | -$0.27 | $0.38 | -$1.54 |
| Diluted EPSper diluted share | $0.02 | $0.05 | -$1.41 | $0.03 | -$2.87 | -$2.93 | -$4.60 | -$2.68 | -$7.45 | -$21.75 | -$49.99 | -$17.99 | -$27.29 | -$0.21 | -$0.27 | $0.36 | -$1.54 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 18, 2026Form 4 | Ye WeiguoChief Operating Officer | SellCommon Stock | 3.0K | $6.35 | $19.1K | 700.0K |
| Jun 11, 2026Form 4 | Ye WeiguoChief Operating Officer | SellCommon Stock | 2.8K | $6.17 | $17.3K | 700.0K |
| Jun 10, 2026Form 4 | Ye WeiguoChief Operating Officer | SellCommon Stock | 5.0K | $6.24 | $31.2K | 700.0K |
| Jun 10, 2026Form 4 | Ye WeiguoChief Operating Officer | SellCommon Stock | 6.4K | $6.21 | $39.9K | 700.0K |
| Jun 9, 2026Form 4 | Ye WeiguoChief Operating Officer | SellCommon Stock | 3.0K | $6.15 | $18.4K | 700.0K |